Participating Companies

The com­pany's ag­on­is­tic mon­o­clo­n­al anti­body molecules of­fer a com­pre­hen­sive pre­clin­i­cal pack­age that si­m­u­lates molec­u­lar and cel­lu­lar re­pair mech­anisms that have the po­ten­tial to re­s­tore or­gan func­tion in pa­tients with fi­brot­ic, in­flam­ma­to­ry, au­toim­mune and de­gen­er­a­tive dis­eas­es, en­abling pa­tients to ben­e­fit from med­i­cal prod­ucts and im­prove their liveli­hood. [more in­for­ma­tion]

Re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ed Ph 3 in Q4 2020; TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts exp YE2021. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023. [more in­for­ma­tion]

In the sum­mer of 2019, Am­ni­otics start­ed build­ing its GMP fa­cil­i­ty, and in June 2020 Am­ni­otics will sub­mit for man­u­fac­tur­ing au­tho­riza­tion of its cell ther­a­peu­tics to the Swedish MPA. Af­ter ap­pro­val Am­ni­otics in­tends to ini­ti­ate clin­i­cal trials, with its most ad­vance prod­uct Pul­mi­Cell™ which is a prod­uct based on MSCs from TAF se­lect­ed for their lung rel­e­vance. [more in­for­ma­tion]

Amo­lyt Phar­ma aims to fur­ther ex­pand and de­vel­op its port­fo­lio by lev­er­ag­ing its glob­al net­work in the field of en­docri­nol­o­gy and with sup­port from a strong syn­di­cate of in­ter­na­tio­n­al in­ves­tors. [more in­for­ma­tion]

De­vel­op­ing first-in-class prod­ucts for the treat­ment of life-threat­en­ing in­fec­tions, with a near-term fo­cus on dead­ly fun­gal patho­gens in vul­n­er­able, im­mune com­pro­mised pa­tients. This makes them sus­cepti­ble to a new dis­ease—in­va­sive fun­gal in­fec­tions. By treat­ing their un­der­ly­ing con­di­tion, pa­tients are now open to a new life-threat­en­ing dis­ease. [more in­for­ma­tion]

We de­vel­op a pipe­line across ther­a­peu­tic ar­eas and part­n­er with Phar­ma for their tar­gets in­clud­ing our $1B+ col­lab­o­ra­tion with Lil­ly for the dis­cov­ery and de­vel­op­ment of trans­la­tion in­hibi­tors of sev­er­al tar­gets. [more in­for­ma­tion]

Arvelle is head­quar­tered in Switz­er­land and re­ceived start-up fi­nanc­ing of $207.8 mil­lion, one of the largest ini­tial fi­nanc­ing com­mit­ments for a Eu­ro­pean-fo­cused bio­phar­ma­ceu­ti­cal com­pany, with in­vest­ments from a glob­al syn­di­cate in­clud­ing No­vaQuest Cap­i­tal Ma­n­age­ment, BRV Cap­i­tal Ma­n­age­ment, LSP, H.I.G. [more in­for­ma­tion]

De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]

De­vel­op­ing/com­mer­cial­iz­ing in­no­va­tive/long-act­ing medicines for se­vere & chron­ic con­di­tions (e.g. opi­oid de­pen­dence, pain, can­cer & en­docrine di­s­or­ders). Fluid­Crys­tal® drug de­liv­ery tech­nolo­gies for im­proved Q of life, treat­ment out­comes and re­source uti­l­iza­tion. [more in­for­ma­tion]

The ba­sis for this is the pro­tein IL1RAP that is in­volved in a num­ber of dis­eas­es and where Can­tar­gia has estab­lished a plat­form. Can­tar­gia's other pro­ject, CAN10, is in the pre­clin­i­cal phase and is aim­ing to de­vel­op an IL1RAP bind­ing anti­body block­ing IL-1, IL-33 and IL-36 - op­ti­mised for the treat­ment of sys­temic scle­ro­sis and my­o­cardi­tis. [more in­for­ma­tion]

Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]

Deutsche Bank’s ADR team is part of the Trust & Agen­cy Ser­vices busi­ness within the new­ly cre­at­ed Cor­po­rate Bank Di­vi­sion. Deutsche Bank was ap­point­ed as DR Bank for the largest Life Sci­ences sec­tor ADR IPO of 2019 with the $582m Nas­daq list­ing of Genmab A/S, con­firm­ing our po­si­tion as the lead­ing is­suer of cap­i­tal in the US ADR mar­kets. [more in­for­ma­tion]

Dy­nacure is a clin­i­cal-stage drug de­vel­op­ment com­pany fo­cused on im­prov­ing the lives of pa­tients with rare and or­phan dis­eas­es. The Dy­nacure team lev­er­ages its proven track re­cord in rare dis­ease drug de­vel­op­ment to build a pipe­line of nov­el drugs. [more in­for­ma­tion]

Gly­costem Ther­a­peu­tics is a Dutch biotech com­pany. Gly­costem Ther­a­peu­tics is the trade name of the le­gal en­ti­ty IPD Ther­a­peu­tics BV, which has been estab­lished in De­cem­ber 2007. Gly­costem Ther­a­peu­tics has de­vel­oped the world's first GMP com­pliant NK-cell plat­form that is ready for in­dus­trial scale-up. [more in­for­ma­tion]

More than 1,000 cor­po­rate and liti­ga­tion at­tor­neys lev­er­age their spe­cif­ic ex­pe­ri­ence and as­sem­ble full-ser­vice teams to ad­vise clients in th­ese and ad­ja­cent in­dus­tries. [more in­for­ma­tion]

Hei­del­berg Phar­ma AG (HPHA, Frank­furt Stock Exchange), based in La­den­burg, Ger­many, is a lead­ing biotech com­pany pi­oneer­ing the use of its AT­AC (Anti­body Tar­get­ed Amanitin Con­ju­gate) plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion ef­fec­tive at spe­cif­i­cal­ly killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. [more in­for­ma­tion]

The com­pany's lead can­di­date is HO­RA-PDE6B, which is in Phase I/II clin­i­cal trials with an in­di­ca­tion in PDE6B re­tini­tis pig­men­tosa. The se­cond prod­uct will en­ter in the clin­ic in H1 2019 The com­pany raised EUR 22.5 mil­lion of Se­ries B ven­ture fund­ing from Kur­ma Part­n­ers, Pon­ti­fax Ven­ture Cap­i­tal, Fund+ on Novem­ber 8, 2017. [more in­for­ma­tion]

is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]

NK-cell plat­form ad­min­is­tered as ad­junct I-O on top of HSCT. Launched FIH POC trial in r/r AML pa­tients (Feb 2020); set to launch ad­di­tio­n­al HSCT trial lat­er in 2020 w/in­ter­im da­ta exp 2021. Pre­sent­ing new da­ta on ex-vi­vo FC21 ex­pand­ed NK-cell ther­a­py in 13 pa­tients at EBMT in 2020. Estab­lished POC in 37 pa­tients to­tal. [more in­for­ma­tion]

glob­al cell ther­a­py com­pany pro­vid­ing pro­pri­e­tary non-vi­ral cell en­gi­neer­ing tech­nol­o­gy for the next gen­er­a­tion of cell-based ther­a­pies in­clud­ing gene edit­ing and im­muno-on­col­o­gy. Max­Cyte may be seen as a play on the cell ther­a­py mar­ket with its blue chip client base. [more in­for­ma­tion]

lead­ing glob­al provider of trad­ing, clear­ing, exchange tech­nol­o­gy, list­ing, in­for­ma­tion and public com­pany ser­vices [more in­for­ma­tion]

First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (Jan 2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]

The com­pany's nov­el eye-drop treat­ments are based on its pro­pri­e­tary sol­u­bi­l­iz­ing nano­par­ti­cle (SNP) tech­nol­o­gy that im­proves both the abil­i­ty to for­mu­late drugs as eye drops and their bioa­vai­l­a­bil­i­ty in the eye tis­sues in­clud­ing both the front and the back of the eye, en­abling hos­pi­tals to pro­vide clients with tech­no­log­i­cal ad­vance­ment in oc­u­lar drug de­liv­ery. [more in­for­ma­tion]

Rev­enue gen­er­at­ing with marine-de­rived and nov­el MoA on­col­o­gy prod­ucts. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­val and up to $550M sales mile­s­tones. [more in­for­ma­tion]

De­vel­op­er of bio­phar­ma­ceu­ti­cals for the treat­ment of an­gio­ge­n­e­sis-re­lat­ed di­s­or­ders. The com­pany is en­gaged in the dis­cov­ery and de­vel­op­ment of nov­el bio­phar­ma­ceu­ti­cal prod­ucts and of­fers anti­body deri­va­tives for the treat­ment of cer­tain can­cers can­cer, rheu­ma­toid arthri­tis and age-re­lat­ed mac­u­lar de­gen­er­a­tion. [more in­for­ma­tion]

PwC is a glob­al net­work of firms de­liv­er­ing as­su­r­ance, tax and con­sult­ing ser­vices for your busi­ness. [more in­for­ma­tion]

Po­ten­tial first in class CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors in Ph1b in AML and high-risk MDS, PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni). Da­ta in 2020. Ear­ly stage pipe­line ad­dress­ing emerg­ing solid tu­mor tar­gets. [more in­for­ma­tion]

Se­qua­na Med­i­cal is a com­mer­cial stage med­i­cal de­vice com­pany de­vel­op­ing the al­fa­pump plat­form for the ma­n­age­ment of fluid over­load in liv­er dis­ease, ma­lig­nant ascites and heart fail­ure. In Eu­rope, the al­fa­pump is CE-marked for the ma­n­age­ment of re­frac­to­ry ascites due to liv­er cir­rho­sis and ma­lig­nant ascites and is in­clud­ed in key clin­i­cal prac­tice guide­lines. [more in­for­ma­tion]

With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]

Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]